← Leaderboards
Ann Cornwall Collier
University Of Washington
$29,777,747
Attributed
$38,344,344
Total exposure
33
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.4M · FY2005–22$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$49,698,718 · 34
By mechanism
U01$18,561,587 · 12
UM1$17,305,685 · 2
P30$11,594,902 · 4
P01$1,595,866 · 2
R01$548,317 · 1
M01$92,361 · 12
Top collaborators
- Rodney J.Y. Ho7 shared
- Nichole Rose Klatt2 shared
Most similar at University Of Washington
Same institution · by research overlap
- Pamela J Fink$12,911,564
- Geoffrey Scott Gottlieb$16,750,227
- Nichole Rose Klatt$11,307,630
- David Chandler Dale$13,804,610
- Daniel R Storm$17,269,477
Others in their field
Top investigators on “Hiv Infections”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
- Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
- Judith S. Currier · University Of California Los Angeles$466,447,923
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
Research focus
Hiv InfectionsClinical ResearchHuman SubjectHuman Therapy EvaluationAids TherapyResearch PersonnelAidsProgramsAntiaids AgentCollaborationsFundingUniversitiesPharmacokineticsCooperative StudyAcquired Immunodeficiency SyndromeUnited States National Institutes Of HealthWashingtonCommunitiesInternationalBaseResearch InfrastructureClinical Trial Phase IDesignProtease Inhibitor
Grant awards (84)
Core B: Developmental$1,277,989
P30 · FY2022 · AI · contact PI
Core B: Developmental$1,147,334
P30 · FY2021 · AI · contact PI
Core B: Developmental$1,201,755
P30 · FY2020 · AI · contact PI
"NextGen Long-acting Platform: Targeted Combination Antiretrovirals"$771,303
U01 · FY2020 · AI · contact PI
Targeted Long-acting Combination Antiretroviral Therapy (TLC-ART)$1,708,470
UM1 · FY2019 · AI
Core B: Developmental$1,267,054
P30 · FY2019 · AI · contact PI
"NextGen Long-acting Platform: Targeted Combination Antiretrovirals"$794,929
U01 · FY2019 · AI · contact PI
Targeting novel pathways to enhance gastrointestinal integrity during HIV infection$331,573
R01 · FY2019 · DK
Targeted Long-acting Combination Antiretroviral Therapy (TLC-ART)$2,946,499
UM1 · FY2018 · AI
Core B: Developmental$1,205,665
P30 · FY2018 · AI · contact PI
Targeting novel pathways to enhance gastrointestinal integrity during HIV infection$216,744
R01 · FY2018 · DK
Targeted Long-acting Combination Antiretroviral Therapy (TLC-ART)$3,352,921
UM1 · FY2017 · AI
Developmental$667,652
P30 · FY2017 · AI · contact PI
Targeted Long-acting Combination Antiretroviral Therapy (TLC-ART)$3,482,643
UM1 · FY2016 · AI
Targeted Long-acting Combination Antiretroviral Therapy (TLC-ART)$3,528,112
UM1 · FY2015 · AI
Clinical Core$293,613
P01 · FY2014 · AI · contact PI
UW Clinical HIV Integrated Research Program$1,031,902
UM1 · FY2013 · AI · contact PI
Developmental$318,780
P30 · FY2013 · AI · contact PI
Clinical Core$255,374
P01 · FY2013 · AI · contact PI
UW Clinical HIV Integrated Research Program$1,255,138
UM1 · FY2012 · AI · contact PI
Developmental$450,250
P30 · FY2012 · AI · contact PI
Clinical Core$249,710
P01 · FY2012 · AI · contact PI
UW Clinical HIV Integrated Research Program$1,055,523
U01 · FY2011 · AI · contact PI
Developmental$395,168
P30 · FY2011 · AI · contact PI
Clinical Core$331,542
P01 · FY2011 · AI · contact PI
UW Clinical HIV Integrated Research Program$1,160,810
U01 · FY2010 · AI · contact PI
Developmental$984,122
P30 · FY2010 · AI · contact PI
Clinical Core$340,629
P01 · FY2010 · AI · contact PI
UW Clinical HIV Integrated Research Program$1,135,374
U01 · FY2009 · AI · contact PI
Developmental$1,077,259
P30 · FY2009 · AI · contact PI
Clinical Cohort$124,998
P01 · FY2009 · AI · contact PI
UW Clinical HIV Integrated Research Program$1,157,590
U01 · FY2008 · AI · contact PI
Developmental$1,069,586
P30 · FY2008 · AI · contact PI
UW Clinical HIV Integrated Research Program$1,131,684
U01 · FY2007 · AI · contact PI
INDUCTIVE EFFECTS OF NELFINAVIR AND RITONAVIR$21,102
M01 · FY2007 · RR · contact PI
COMPARISON OF INITIAL ANTRETROVIRAL REGIMENS (HIV)$979
M01 · FY2007 · RR · contact PI
LOPINAVIR PHARMACOKINETICS IN MEN AND WOMEN (HIV)$979
M01 · FY2007 · RR · contact PI
URIDINE SUPPLEMENTATION FOR TREATMENT OF HIV LIPOATROPHY$490
M01 · FY2007 · RR · contact PI
ADULT AIDS CLINICAL TRIALS UNIT$1,469,323
U01 · FY2006 · AI · contact PI
COMPARISON OF INITIAL ANTRETROVIRAL REGIMENS$11,549
M01 · FY2006 · RR · contact PI
LOPINAVIR PHARMACOKINETICS IN MEN AND WOMEN$4,621
M01 · FY2006 · RR · contact PI
ADULT AIDS CLINICAL TRIALS UNIT$1,589,759
U01 · FY2005 · AI
ADULT AIDS CLINICAL TRIALS UNIT$1,591,480
U01 · FY2004 · AI
Core-Developmental$353,840
P30 · FY2004 · AI
PK interaction of APV, EFV, II protease inhibitor in HIV-seronegative volunteer$24,528
M01 · FY2004 · RR
PK STUDY (ACTG 514S) OF LOPINAVIR/RITONAVIR AND GW 433908$1,065
M01 · FY2004 · RR
ADULT AIDS CLINICAL TRIALS UNIT$1,643,516
U01 · FY2003 · AI
ADULT AIDS CLINICAL TRIALS UNIT$1,625,604
U01 · FY2002 · AI
IMMUNOLOGY AND IMMUNE BASED THERAPY AGENDA$0
U01 · FY2002 · AI
NEUROLOGY AGENDA$0
U01 · FY2002 · AI
COMPLICATIONS OF HIV DISEASE AGENDA$0
U01 · FY2002 · AI
HIV DISEASE RESEARCH AGENDA$0
U01 · FY2002 · AI
CORE--DEVELOPMENTAL$0
P30 · FY2002 · AI
AMPRENAVIR IN COMBINATION WITH 3 PROTEASE INHIBITORS$0
M01 · FY2002 · RR
PHASE I AND II STUDY OF PMPA$0
M01 · FY2002 · RR
CORE--ADVANCED TECHNOLOGY LABORATORIES$0
U01 · FY2002 · AI
OUTREACH AGENDA$0
U01 · FY2002 · AI
OUTCOMES COMMITTEE AGENDA$0
U01 · FY2002 · AI
WOMEN'S HEALTH AGENDA$0
U01 · FY2002 · AI
PHARMACOLOGY AGENDA$0
U01 · FY2002 · AI
ADULT AIDS CLINICAL TRIALS UNIT$1,950,196
U01 · FY2001 · AI
COMPLICATIONS OF HIV DISEASE AGENDA$0
U01 · FY2001 · AI
CORE--ADVANCED TECHNOLOGY LABORATORIES$0
U01 · FY2001 · AI
OUTREACH AGENDA$0
U01 · FY2001 · AI
OUTCOMES COMMITTEE AGENDA$0
U01 · FY2001 · AI
WOMEN'S HEALTH AGENDA$0
U01 · FY2001 · AI
PHARMACOLOGY AGENDA$0
U01 · FY2001 · AI
IMMUNOLOGY AND IMMUNE BASED THERAPY AGENDA$0
U01 · FY2001 · AI
NEUROLOGY AGENDA$0
U01 · FY2001 · AI
HIV DISEASE RESEARCH AGENDA$0
U01 · FY2001 · AI
CORE--DEVELOPMENTAL$0
P30 · FY2001 · AI
AMPRENAVIR IN COMBINATION WITH 3 PROTEASE INHIBITORS$0
M01 · FY2001 · RR
PHASE I AND II STUDY OF PMPA$0
M01 · FY2001 · RR
ADULT AIDS CLINICAL TRIALS UNIT$1,484,496
U01 · FY2000 · AI
CORE--DEVELOPMENTAL$178,448
P30 · FY2000 · AI
PHASE I AND II STUDY OF PMPA$3,864
M01 · FY2000 · RR
PHASE II STUDY OF INTERLEUKIN 2 IN PATIENTS ON ANTIRETROVIRAL THERAPY$3,864
M01 · FY2000 · RR
PHASE II STUDY OF INTERLEUKIN 2 IN PATIENTS ON ANTIRETROVIRAL THERAPY$3,864
M01 · FY2000 · RR
AMPRENAVIR IN COMBINATION W/ 3 PROTEASE INHIBITORS$3,864
M01 · FY2000 · RR
EFAVIRENZ OR NELFINAVIR W/ LAMIVUDINE/ZIDOVUDINE IN HIV$3,864
M01 · FY2000 · RR
EFAVIRENZ OR NELFINAVIR W/ LAMIVUDINE/ZIDOVUDINE IN HIV$3,864
M01 · FY2000 · RR
PHASE I AND II STUDY OF PMPA$3,864
M01 · FY2000 · RR
VIRAL ACTIVATION TRANSFUSION STUDY$0
N01 · FY2000 · HB
AMPRENAVIR IN COMBINATION WITH 3 PROTEASE INHIBITORS$0
M01 · FY2000 · RR